UBS analyst Ashwani Verma raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $20 from $13 and keeps a Buy rating on the shares. The stock is up 20% following the Q2 results, driven by Lumryz’s strong beat and positive sustainable trends in the base Narcolepsy business, the analyst tells investors in a research note. UBS continues to see favorable risk/reward heading into 2H25 and 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Reports Strong Earnings and Growth
- Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank
- Avadel Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright
- Avadel Pharmaceuticals Reports Strong Q2 Growth
- Avadel Pharmaceuticals reports Q2 EPS 10c, consensus 3c